ClinicaliQ Trial Snapshot
- Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN2230 in Healthy Participants — Recruiting • Phase I • NCT07352423.
- ALXN2230 single injection tested for safety and tolerability in healthy volunteers.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The primary objective of this study is to evaluate the safety and tolerability of single subcutaneous (SC) doses of ALXN2230 in healthy participants. Conditions: Healthy Adult Participants Interventions: ALXN2230, Placebo Lead Sponsor: Alexion Pharmaceuticals, Inc. Planned Enrollment: 48 participants